Drugs /

omo-1

Back to Drugs List

Overview

NCI Definition [1]:
An inhibitor of the proto-oncogene and receptor tyrosine kinase (RTK) hepatocyte growth factor receptor (c-Met; HGFR; MET) with potential antineoplastic activity. Upon administration, OMO-1 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

Clinical Trials

View Clinical Trials for omo-1

Omo-1 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating omo-1, 1 is phase 1/phase 2 (0 open).

EGFR Mutation, MET Amplification, and MET Mutation are the most frequent biomarker inclusion criteria for omo-1 clinical trials.

Malignant solid tumor is the most common disease being investigated in omo-1 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Omo-1
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating omo-1 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
omo1, jnj-38877618, met kinase inhibitor omo-1
Drug Target(s) [2]:
MET
NCIT ID [1]:
C148537

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.